TD Cowen on Roivant Sciences (ROIV): 'We are overall very encouraged by this given importance of the molar ratio patents to ABUS' case'
Tweet Send to a Friend
TD Cowen analyst Yaron Werber reiterated a Buy rating on Roivant Sciences (NASDAQ: ROIV).The analyst comments "The judge sided w/3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
